216 related articles for article (PubMed ID: 32517891)
1. [French CCAFU guidelines on prostate cancer: hormone-sensitive metastatic prostate cancer-update 2020].
Rozet F; Hennequin C; Beuzeboc P; Mathieu R; Mongiat-Artus P; Beauval JB; Cormier L; Fromont-Hankard G; Ploussard G; Renard-Penna R; Brureau L; Méjean A
Prog Urol; 2020; 30(8-9):430-438. PubMed ID: 32517891
[TBL] [Abstract][Full Text] [Related]
2. [French ccAFU guidelines - update 2020-2022: prostate cancer].
Rozet F; Mongiat-Artus P; Hennequin C; Beauval JB; Beuzeboc P; Cormier L; Fromont-Hankard G; Mathieu R; Ploussard G; Renard-Penna R; Brenot-Rossi I; Bruyere F; Cochet A; Crehange G; Cussenot O; Lebret T; Rebillard X; Soulié M; Brureau L; Méjean A
Prog Urol; 2020 Nov; 30(12S):S136-S251. PubMed ID: 33349424
[TBL] [Abstract][Full Text] [Related]
3. French AFU Cancer Committee Guidelines - Update 2022-2024: prostate cancer - Management of metastatic disease and castration resistance.
Ploussard G; Roubaud G; Barret E; Beauval JB; Brureau L; Créhange G; Dariane C; Fiard G; Fromont G; Gauthé M; Renard-Penna R; Rozet F; Ruffion A; Sargos P; Mathieu R; Rouprêt M;
Prog Urol; 2022 Nov; 32(15):1373-1419. PubMed ID: 36400484
[TBL] [Abstract][Full Text] [Related]
4. Novel Insights into the Management of Oligometastatic Prostate Cancer: A Comprehensive Review.
Battaglia A; De Meerleer G; Tosco L; Moris L; Van den Broeck T; Devos G; Everaerts W; Joniau S
Eur Urol Oncol; 2019 Mar; 2(2):174-188. PubMed ID: 31017094
[TBL] [Abstract][Full Text] [Related]
5. [French ccAFU guidelines - Update 2018-2020: Prostate cancer].
Rozet F; Hennequin C; Beauval JB; Beuzeboc P; Cormier L; Fromont-Hankard G; Mongiat-Artus P; Ploussard G; Mathieu R; Brureau L; Ouzzane A; Azria D; Brenot-Rossi I; Cancel-Tassin G; Cussenot O; Rebillard X; Lebret T; Soulié M; Renard Penna R; Méjean A
Prog Urol; 2018 Nov; 28 Suppl 1():R81-R132. PubMed ID: 31610875
[TBL] [Abstract][Full Text] [Related]
6. Recent trends in the management of advanced prostate cancer.
Ritch C; Cookson M
F1000Res; 2018; 7():. PubMed ID: 30345007
[TBL] [Abstract][Full Text] [Related]
7. [Docetaxel or abiraterone in combination with androgen deprivation therapy for metastatic prostate cancer].
Hammerer P; Manka L
Urologe A; 2019 Oct; 58(10):1185-1197. PubMed ID: 31127324
[TBL] [Abstract][Full Text] [Related]
8. Indirect Comparisons of Efficacy between Combination Approaches in Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Network Meta-analysis.
Sathianathen NJ; Koschel S; Thangasamy IA; Teh J; Alghazo O; Butcher G; Howard H; Kapoor J; Lawrentschuk N; Siva S; Azad A; Tran B; Bolton D; Murphy DG
Eur Urol; 2020 Mar; 77(3):365-372. PubMed ID: 31679970
[TBL] [Abstract][Full Text] [Related]
9. A multidisciplinary consensus statement on the optimal pharmacological treatment for metastatic hormone-sensitive prostate cancer.
Borque-Fernando A; Calleja-Hernández MA; Cózar-Olmo JM; Gómez-Iturriaga A; Pérez-Fentes DA; Puente-Vázquez J; Rodrigo-Aliaga M; Unda M; Álvarez-Ossorio JL
Actas Urol Esp (Engl Ed); 2023 Mar; 47(2):111-126. PubMed ID: 36720305
[TBL] [Abstract][Full Text] [Related]
10. Treatment in hormone-sensitive metastatic prostate cancer: factors to consider when personalizing therapy.
Aragon-Ching JB; Dreicer R
Expert Rev Anticancer Ther; 2020 Jun; 20(6):483-490. PubMed ID: 32406281
[TBL] [Abstract][Full Text] [Related]
11. Addition of Docetaxel to Androgen Deprivation Therapy for Patients with Hormone-sensitive Metastatic Prostate Cancer: A Systematic Review and Meta-analysis.
Tucci M; Bertaglia V; Vignani F; Buttigliero C; Fiori C; Porpiglia F; Scagliotti GV; Di Maio M
Eur Urol; 2016 Apr; 69(4):563-573. PubMed ID: 26422676
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Abiraterone Acetate and Docetaxel with Androgen Deprivation Therapy in High-risk and Metastatic Hormone-naïve Prostate Cancer: A Systematic Review and Network Meta-analysis.
Wallis CJD; Klaassen Z; Bhindi B; Goldberg H; Chandrasekar T; Farrell AM; Boorjian SA; Kulkarni GS; Karnes RJ; Satkunasivam R
Eur Urol; 2018 Jun; 73(6):834-844. PubMed ID: 29037513
[TBL] [Abstract][Full Text] [Related]
13. [CCAFU french national guidelines 2016-2018 on prostate cancer].
Rozet F; Hennequin C; Beauval JB; Beuzeboc P; Cormier L; Fromont G; Mongiat-Artus P; Ouzzane A; Ploussard G; Azria D; Brenot-Rossi I; Cancel-Tassin G; Cussenot O; Lebret T; Rebillard X; Soulié M; Renard-Penna R; Méjean A
Prog Urol; 2016 Nov; 27 Suppl 1():S95-S143. PubMed ID: 27846936
[TBL] [Abstract][Full Text] [Related]
14. Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer.
Chi KN; Agarwal N; Bjartell A; Chung BH; Pereira de Santana Gomes AJ; Given R; Juárez Soto Á; Merseburger AS; Özgüroğlu M; Uemura H; Ye D; Deprince K; Naini V; Li J; Cheng S; Yu MK; Zhang K; Larsen JS; McCarthy S; Chowdhury S;
N Engl J Med; 2019 Jul; 381(1):13-24. PubMed ID: 31150574
[TBL] [Abstract][Full Text] [Related]
15. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.
Gravis G; Fizazi K; Joly F; Oudard S; Priou F; Esterni B; Latorzeff I; Delva R; Krakowski I; Laguerre B; Rolland F; Théodore C; Deplanque G; Ferrero JM; Pouessel D; Mourey L; Beuzeboc P; Zanetta S; Habibian M; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Labourey JL; Machiels JP; El Kouri C; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Soulie M
Lancet Oncol; 2013 Feb; 14(2):149-58. PubMed ID: 23306100
[TBL] [Abstract][Full Text] [Related]
16. [Metachronous oligometastatic prostate cancer-the more the better or only local treatment?].
Steuber T; Maurer T; Miller K
Urologe A; 2021 Dec; 60(12):1534-1545. PubMed ID: 34734294
[TBL] [Abstract][Full Text] [Related]
17. Metastasis-Directed Therapy for Oligometastatic Castration-Sensitive Prostate Cancer: An Alternative to ADT?
Cahill EM; Pfail JL; Fu MZ; Saraiya B; Mayer T; Stephenson RD; Ennis RD; Hathout L; Deek MP; Ghodoussipour S; Jang TL
Curr Urol Rep; 2023 Jul; 24(7):299-306. PubMed ID: 37017928
[TBL] [Abstract][Full Text] [Related]
18. Systemic treatment options for metastatic hormone-sensitive prostate cancer: making sense of the data.
Baston C; Preda A; Guler-Margaritis SS; Sinescu I; Gingu C
Curr Opin Urol; 2020 Jul; 30(4):576-583. PubMed ID: 32427630
[TBL] [Abstract][Full Text] [Related]
19. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline.
Loblaw DA; Virgo KS; Nam R; Somerfield MR; Ben-Josef E; Mendelson DS; Middleton R; Sharp SA; Smith TJ; Talcott J; Taplin M; Vogelzang NJ; Wade JL; Bennett CL; Scher HI;
J Clin Oncol; 2007 Apr; 25(12):1596-605. PubMed ID: 17404365
[TBL] [Abstract][Full Text] [Related]
20. Management of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): an Evolving Treatment Paradigm.
Weiner AB; Nettey OS; Morgans AK
Curr Treat Options Oncol; 2019 Jul; 20(9):69. PubMed ID: 31286275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
